FOX04-DRI — Senolytic Peptide

What Is FOX04-DRI?

FOX04-DRI is a modified peptide designed to selectively induce apoptosis (programmed cell death) in senescent cells — cells that have stopped dividing but refuse to die, accumulating with age and secreting inflammatory factors. Published in a landmark 2017 Cell paper by researchers at Erasmus University Medical Center, it represents one of the most targeted senolytic approaches in longevity research.

Mechanism of Action

FOX04-DRI works by disrupting the interaction between FOXO4 and p53 in senescent cells. Normally, FOXO4 sequesters p53 in the nucleus, preventing p53 from triggering apoptosis — which is how senescent cells evade programmed death. FOX04-DRI competes with endogenous FOXO4, releasing p53 to induce apoptosis selectively in senescent cells while leaving healthy cells unaffected.

Key Research Findings

• Senescent cell clearance — The 2017 Cell study demonstrated selective elimination of senescent cells in aged mice
• Physical restoration — Treated aged mice showed restored fitness, fur density, and renal function
• Selective toxicity — In vitro studies confirm apoptosis induction in senescent cells with minimal effect on proliferating cells
• Aging biomarkers — Reduced senescence-associated secretory phenotype (SASP) markers in treated animals
• D-retro-inverso design — The DRI modification provides protease resistance and improved bioavailability

Known Side Effects

Limited safety data exists beyond the original preclinical studies. The selective mechanism should theoretically spare healthy cells, but potential off-target effects at higher doses are not well characterized. Cost is also a practical consideration — FOX04-DRI is one of the most expensive research peptides available.

Legal Status (2026)